Three years into a PhIII program for a failed Duchenne MD drug, Catabasis hauls down the flag and admits defeat
Three years ago, Catabasis CEO Jill Milne and the crew insisted they had found good reason for great cheer once they plumbed the data from …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
